Preclinical colorectal cancer chemopreventive efficacy and p53-modulating activity of 3′,4′,5′-trimethoxyflavonol, a quercetin analogue

Cancer Prevention Research

Volumn 3, Issue 8, 2010, Pages 929-939

  Howells, Lynne M ^a   Britton, Robert G ^a   Mazzoletti, Marco ^b   Greaves, Peter ^a   Broggini, Massimo ^b   Brown, Karen ^a   Steward, William P ^a   Gescher, Andreas J ^a   Sale, Stewart ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3',4',5' TRIMETHOXYFLAVONOL; CASPASE 3; FISETIN; KI 67 ANTIGEN; PROTEIN P53; QUERCETIN; QUERCETIN DERIVATIVE; UNCLASSIFIED DRUG;

AMES TEST; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CANCER INHIBITION; CANCER PREVENTION; CANCER SIZE; CELL STRAIN HCT116; CHEMOPROPHYLAXIS; COLON POLYP; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA; CHEMOPREVENTION; COLORECTAL NEOPLASMS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FLAVONOIDS; GENES, P53; HCT116 CELLS; HUMANS; MICE; MICE, NUDE; MICE, TRANSGENIC; QUERCETIN; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955465664     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0236     Document Type: Article

References (46)

1. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
2. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
3. Dube C, Rostom A, Lewin G, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Intern Med 2007;146:365-75.
4. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast-cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
5. Deschner ES, Ruperto J, Wong G, Newmark HL. Quercetin and rutin as inhibitors of azoxymethanol-induced colonic neoplasia. Carcinogenesis 1991;12:1193-6.
6. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Nat Acad Sci USA 2001;98:10350-5.
7. Lamartiniere CA, Moore JB, Brown NM, et al. Genistein suppresses mammary cancer in rats. Carcinogenesis 1995;16:2833-40.
8. Walle T, Ta N, Kawamori T, et al. Cancer chemopreventive properties of orally bioavailable flavonoids - methylated versus unmethylated flavones. Biochem Pharmacol 2007;73:1288-96.
9. Cai H, Sale S, Schmid R, et al. Flavones as colorectal cancer chemopreventive agents - phenol-O-methylation enhances efficacy. Cancer Prev Res 2009;2:743-50.
10. Plaumann B, Fritsche M, Rimpler H, et al. Flavonoids activate wildtype p53. Oncogene 1996;13:1605-14.
11. Avila MA, Velasco JC, Cansado J, Notario V. Quercetin mediates the down regulation of mutant p53 in the human breast cancer cell line MDA-MB468. Cancer Res 1994;54:2424-8.
12. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001;1:68-76.
13. Vousden K. P53 death star. Cell 2000;103:601-4.
14. Kopelovitch I, DeLeo AB. Elevated levels of p53 antigen in cultured skin fibroblasts from patients with hereditary adenocarcinoma of the colon and rectum and its relevance to oncogenic mechanisms. J Natl Cancer Inst 1986;77:1241-6.
15. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99.
16. Wang W, Kim SH, El-Deiry WS. Small molecule modulators of p53 family signaling and anti-tumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci USA 2006;103:11003-8.
17. min/+ mice. Cancer Res 2008;68:7670-5.
18. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992;256:668-70.
19. Makita H, Tanaka T, Fujitsuka H, et al. Chemoprevention of 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis by the dietary flavonoids chalcone, 2-hydroxychalcone, and quercetin. Cancer Res 1996;56:4904-9.
20. De S, Chakraborty J, Chakraborty RN, Das S. Chemopreventive activity of quercetin during carcinogenesis in cervix uteri in mice. Phytotherapy Res 2000;14:347-51.
21. Khanduja KL, Gandhi RK, Pathania V, Syal N. Prevention of Nnitrosodiethylamine-induced lung tumorigenesis by ellagic acid and quercetin in mice. Food Chem Toxicol 1999;37:313-8.
22. Ferry DR, Smith A, Malkhandi J, et al. Phase 1 clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 1996;2:659-68.
23. Khan N, Asim M, Afaq F, et al. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res 2008;68:8555-63.
24. Czeczot H, Tudek B, Kusztelak J, et al. Isolation and studies of the mutagenic activity in the Ames test of flavonoids naturally occurring in medical herbs. Mutat Res 1990;240:209-16.
25. Mc Gregor JT, Jurd L. Mutagenicity of plant flavonoids: structural requirements for mutagenic activity in Salmonella typhimurium. Mutat Res 1978;54:297-309.
26. Jurado J, Alejandre-Duran E, Alonso-Moraga A, Pueyo C. Study on the mutagenic activity of 13 bioflavonoids with the Salmonella Ara test. Mutagenesis 1991;6:289-95.
27. Rietjens IMCM, Boersma MG, Van der Woude H, et al. Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk. Mutat Res 2005;574:124-38.
28. IARC Monographs on the evaluation of carcinogenic risk of chemicals to humans 31. Some food additives, feed additives and naturally occurring substances. Lyon 1983:213-29.
29. IARC Monographs on the evaluation of carcinogenic risk of chemicals to humans 73. Some chemicals that cause tumours of the kidney or urinary bladder in rodents and some other substances. Lyon 1999:497-515.
30. De Giovanni C, Landuzzi L, Nicoletti G, et al. Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. Int J Cancer 2004;109:200-6.
31. Min mouse model in vivo. Eur J Cancer 2009;45:2731-5.
32. Britton R, Fong I, Saad S, et al. Synthesis of the novel flavonoid 3′,4′,5′-trimethoxyflavonol and its determination in plasma and tissues of mice by HPLC with fluorescence detection. J Chromatogr B 2009;877:939-42.
33. Perkins S, Verschoyle RD, Hill K, et al. Chemopreventive efficacy and pharmacokinetics of curcumin in the Min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2002;11:535-40.
34. Workman P, Twentyman P, Balkwill F, et al. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Brit J Cancer 1998;77:1-10.
35. Sale S, Tunstall RG, Ruparelia KC, Potter GA, Steward WP, Gescher AJ. Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analogue trans 3,4,5,4′-tetramethoxystilbene (DMU-212) on adenoma development in the ApcMin+ mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int J Cancer 2005;115:194-201.
36. Cooke D, Schwarz M, Boocock D, et al. Effect of cyanidin-3-glucoside and an anthocyanin mixture from bilberry on adenoma development in the ApcMin mouse model of intestinal carcinogenesis - relationship with tissue anthocyanin levels. Int J Cancer 2006;119:2213-20.
37. Goodlad RA, Ryan AJ, Wedge SR, et al. Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the Apc(Min/+) mouse model of early intestinal cancer. Carcinogenesis 2006;27:2133-9.
38. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:148-54.
39. Mahmoud NN, Carothers AM, Grunberger D, et al. Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis 2000;21:921-7.
40. Yang K, Lamprecht SA, Liu Y, et al. Chemoprevention studies of the flavonoids quercetin and rutin in normal and azoxymethane-treated mouse colon. Carcinogenesis 2000;21:1655-60.
41. Pereira MA, Grubbs CJ, Barnes LH, et al. Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. Carcinogenesis 1996;17:1305-11.
42. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;50:219-44.
43. Tanigawa S, Fujii M, Hou DX. Stabilization of p53 is involved in quercetin-induced cell cycle arrest and apoptosis in HepG2 cells. Biosci Biotechnol Biochem 2008;73:797-804.
44. Lim DY, Park JHY. Induction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin. Am J Physiol Gastrointest Liver Physiol 2009;296:G1060-8.
45. Shukla S, Gupta S. Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. Mol Cancer Ther 2006;5:843-52.
46. Lim JH, Park JW, Min DS, et al. NAG-1 up-regulation mediated by EGR-1 and p53 is critical for quercetin-induced apoptosis in HCT116 colon carcinoma cells. Apoptosis 2007;12:411-21.